About the Award: The EANO Award is given to scientists who have made an outstanding contribution to the developments in the field of Neuro-Oncology, or to people having greatly contributed to the improvement of patient care at different levels.
RECIPIENT: Jean-Yves Delattre
Jean-Yves Delattre trained in Neurology in Paris, France. He did a Neuro-Oncology fellowship at Memorial Sloan Kettering Cancer Center (New York, NY, USA) with Dr Jerome B. Posner (1985-1988). He was appointed professor of Neurology at the University Pierre and Marie Curie (UPMC), Paris VI in 1992. From 1998 to 2012, he was chairman of the department of Neurology “Mazarin” and head of the laboratory of experimental Neuro-Oncology (Inserm) at the Salpêtrière Hospital, Paris, France. He is currently chief, Pole of Nervous System Diseases (a group of 10 departments of clinical neurosciences) and medical director of the Institute of Translational Neurosciences at the Salpêtrière Hospital (IHU-UPMC). He is past-president of the ANOCEF (French Association of Neuro-Oncologists) and of the EANO (2000-2002). He was on the editorial board of the Journal of Clinical Oncology (Neuro-Oncology section, 2006-2012) and is on the editorial board of “The Oncologist”. He is co-author of 335 papers (H index, 62).
JY Delattre contributed to the development of Neuro-Oncology in France and in Europe, particularly through the design, conduct or participation of the “Salpêtrière group” in multicentric trials on gliomas and lymphomas through the ANOCEF and EORTC. He had a special concern for gliomas in the elderly and conducted the randomized trial showing the superiority of radiotherapy over supportive care alone in elderly patients with glioblastoma. As director of the Salpêtrière CNS tumor bank and coordinator of the national network on anaplastic oligodendrogliomas (POLA), he also contributed with his group and others to the study of the natural history of low grade gliomas, to genotype-phenotype correlations in gliomas, particularly the prognostic value of IDH1 mutation and the correlation between molecular profile of gliomas and response to treatment.
Finally, as a general Neuro-Oncologist, he participated in several studies on paraneoplastic neurologic syndromes, treatment neurotoxicity and brain metastases.
PRINT THIS PAGE